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Abstract 
There are many metabolic disorders that present with bone phenotypes. In 
some cases, the pathological bone symptoms are the main features of the 
disease whereas in others they are a secondary characteristic. In general, the 
generation of the bone problems in these disorders is not well understood and 
the therapeutic options for them are scarce. Bone development occurs in the 
early stages of embryonic development where the bone formation, or 
osteogenesis, takes place. This osteogenesis can be produced through the 
direct transformation of the preexisting mesenchymal cells into bone tissue 
(intramembranous ossification) or by the replacement of the cartilage by bone 
(endochondral ossification). On the contrary, bone remodeling takes place 
during the bone’s growth, after the bone development, and continues 
throughout the whole life. The remodeling involves the removal of mineralized 
bone by osteoclasts followed by the formation of bone matrix by the 
osteoblasts, that subsequently becomes mineralized. In some metabolic 
diseases bone pathological features are associated with bone development 
problems but in others they are associated with bone remodeling. Here we 
describe three examples of impaired bone development or remodeling in 
metabolic diseases, including work by others and results from our research. In 
particular, we will focus on hereditary multiple exostosis (or 
osteochondromatosis), Gaucher disease and the susceptibility to atypical 
femoral fracture in patients treated with bisphosphonates for several years. 
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Osteochondromatosis or multiple hereditary exostosis. 
Osteochondromatosis is characterized by the growth of multiple benign tumours 
mainly in long bones. The disease belongs to the group of congenital disorders 
of glycosylation. In particular, it is a defect of O-glycosylation. It is inherited as 
an autosomal dominant disease and it is caused by monoallelic mutations either 
in the EXT1 or in the EXT2 genes (reviewed in Wuyts and van Hul 2000). As a 
consequence of this, the alternative name for the disorder is EXT1/EXT2-CDG. 
The EXT1 (exostosin 1) and EXT2 (extosin 2) proteins form a co-polymerase 
involved in heparan sulfate biosynthesis.  
The disease is related to bone development. Endochondral ossification is 
one of the two essential processes during fetal development of the mammalian 
skeletal system, by which bone tissue is created through the replacement of 
growing cartilage by bone (the other process is intramembranous ossification). 
In long bones there is a region, called the growth plate, in which chondrocytes 
proliferate and are replaced by osteoblasts. In this process, several signaling 
molecules play key roles in the regulation and direction of bone growth 
(Stickens and Evans 1998). Extracellular heparan sulfate makes a barrier that 
regulates the flux of these molecules. Individuals with an inherited mutation in 
one allele of EXT1 or EXT2 can suffer a second (somatic) mutation in the wild-
type allele. This will lead to a local lack of heparan sulfate and an impaired 
regulation of bone growth, giving rise to osteochondromas (Bovee 2010). The 
role of heparan sulfate in the dis ease has been recently reviewed by Maurizio 
This article is protected by copyright. All rights reserved.
Pacifici (2018). The decrease in exostosin and heparan sulfate levels caused by 
the second hit (the somatic mutation in the wild-type allele of the EXT gene with 
a germline mutation in the other allele), causes a decrease in signaling 
molecules such as FGF, MEK, ERK, Noggin and Gremlin, and an increase of 
BMP and Hh signaling and of heparanase, which are involved in the abnormal 
growing of bone. For this reason, this disease can be considered as an 
example of abnormal bone development. The most severe complication of 
osteochondromatosis is malignant transformation of an osteochondroma into a 
peripheral secondary chondrosarcoma. The estimated lifelong risk varies 
among different studies from 1% to 25% (Beltrami et al. 2016). Czajka and 
DiCaprio (2015) studied a large international, heterogeneous cohort of around 
800 patients with multiple hereditary exostoses and reported a proportion of 
2.7% of malignant degeneration to chondrosarcoma. The mechanisms for this 
malignant change are not clear. Different authors reported genetic mutations in 
genes different from EXT1 and EXT2 during chondrosarcoma progression and it 
is assumed that these are necessary to progress into malignancy (Musso et al. 
2015, and references therein). Musso et al. (2015) described a surprising case 
in which they observed a loss of the EXT2 mutant allele in the peripheral 
secondary chondrosarcoma, instead of the expected loss of the EXT2 wild-type 
allele, suggesting a different cell of origin for osteochondromas and 
chondrosarcomas. However, this is a topic that is still open. 
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Our group has studied the mutations present in Spanish (Sarrion et al. 
2013) and Latino American (Delgado et al. 2012, 2014, Cammarata-Scalisi et 
al. 2015, 2018) patients. In general, we sequenced PCR-amplified exons and 
flanking regions of the EXT1 and EXT2 genes, followed by MLPA analysis if the 
sequencing of the exons gave negative results. In some cases, we observed 
mosaicism in the first affected individual of the family (Sarrion et al. 2013). 
Occasionally, one of the parents of the proband, with a very mild phenotype, 
learned about his/her disease after our analysis of the family. In one particular 
case, a patient came to us after having obtained negative results both of 
sequencing and MLPA analyses by a private molecular diagnosis company. We 
thought that she could either bear a hidden mutation in EXT1 or EXT2, or bear 
a mutation in a hypothetical EXT3 gene, suggested to exist but never found. We 
resequenced the EXT1 and EXT2 genes and with some of the SNPs found in 
the resequencing we performed a segregation analysis in the patient’s family to 
see if we were able to discard the involvement of these two genes in their 
disease. The result was the opposite: the segregation analysis showed an 
apparent lack of heredity of EXT2, only consistent with a deletion (Fig. 1a, 1b), 
which we demonstrated afterwards by MLPA (Fig. 1c). It was a serious mistake 
of the private company. 
As mentioned above, osteochondromatosis is inherited as an autosomal 
dominant disease. Thus, only a mutation in one allele of either EXT1 or EXT2 is 
present in the germline. Until a few years ago, no case with germline mutations 
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in the two alleles of these genes was known. However, two cases with 
homozygous germline missense mutations in the EXT2 gene have been 
recently published (Farhan et al. 2015, El-Bazzal et al. 2019). Surprisingly, the 
phenotype is characterized by seizures and developmental disorders without 
exostoses. The only bone phenotype was osteopenia, present in one of the 
patients. The proposed name for this novel syndrome is autosomal recessive 
EXT2-related syndrome (AREXT2). Notably, these cases show that the 
consequences of these homozygous missense mutations are critical for brain 
development, while not affecting bone. The role of heparan sulfate in the brain 
is not well understood but very recently, it was shown that it organizes neuronal 
synapses through neurexin partnerships (Zhang et al. 2018). Further research 
will be necessary to better understand the dual roles of EXT2 in bone and brain. 
We have also studied the family of EXT genes from a different point of 
view. In Sanfilippo disease (mucopolysaccharidosis III) there is an accumulation 
of heparan sulfate in the lysosomes due to an impaired function of one of 
several lysosomal enzymes. We have assayed the inhibition of the EXTL2 and 
EXTL3 genes, as a substrate reduction therapy for Sanfilippo C disease in 
patients’ fibroblasts (Canals et al. 2015a) and we are currently performing a 
similar approach on Sanfilippo C neurons, derived from iPSC generated by our 
group (Canals et al. 2015b). 
 
Gaucher disease 
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Lysosomal storage diseases (LSDs) are a group of more than 50 disorders, 
which mainly result from the deficient activity of specific lysosomal enzymes. 
This deficiency produces a progressive accumulation of specific substrates 
affecting different biochemical or cellular pathways, which subsequently will 
cause the tissue pathology (Futerman and van Meer 2004). Gaucher disease 
(GD), the most common LSD, is caused by mutations in the GBA1 gene (MIM# 
606463) that produce a defective activity of glucocerebrosidase (EC 3.2.1.45; 
GBA1), the lysosomal enzyme responsible for the hydrolysis of 
glucosylceramide (GlcCer) into glucose and ceramide. As a result of this 
autosomal recessive genetic defect, GlcCer and glucosylsphingosine (GlcSph) 
accumulate in the lysosomes of macrophages (revised by Sidransky 2004) 
generating the typical "Gaucher cells", the hallmark of the disease. Based on 
the absence or presence and severity of neuronopathic involvement, GD has 
been classified into three clinical phenotypes, non-neuronopathic (GD1), acute 
neuronopathic (GD2) and chronic or subacute neuronopathic (GD3) (Beutler 
and Grabowski 1995). An extreme phenotypic variability has been reported for 
Gaucher disease, within each of the clinical types, and even among patients 
with the same mutations. This variability is likely due to a multitude of factors 
such as genetic background, environment, and epigenetic status (Sidransky 
2004). Davidson et al. (2018) reviewed genetic modifiers that influence the 
phenotypic outcome of Gaucher disease. 
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GD1 is the most frequent form of the disease and it is characterized by 
heterogeneous manifestations including visceral (hepatosplenomegaly), 
hematological and skeletal symptoms. Bone involvement affects up to 90% of 
GD1 patients and it is for them the most debilitating feature because it has a 
major impact on their life quality (Giraldo 2005). Skeletal manifestations include 
erlenmeyer flask deformity, fractures due to osteopenia or osteoporosis, 
osteosclerosis, osteonecrosis, bone pain, bone crisis, growth retardation during 
childhood and, rarely, acute osteomyelitis (Mikosch and Hughes 2010). The 
majority of these manifestations could be explained by the disruption of the 
balance between osteoblastic bone formation and osteoclastic bone resorption. 
The markers of bone metabolism are useful to measure changes in the 
activities of osteoblasts and osteoclasts. However, controversial results on the 
alteration of bone formation and of bone resorption markers in GD and their 
response to enzyme therapy have been reported (revised by van Dussen et al. 
2011). Furthermore, we do not have a conclusive statement from previous 
studies where mouse or cell models were used to understand bone pathology in 
GD. Basically, the lack of consistence between studies is an evidence that the 
bone pathology in GD is complex and, based on the wide phenotypic spectrum 
in patients, may be a pleiotropic disease. 
Campeau et al. (2009) revealed that Mesenchymal Stromal Cells (MSCs) 
from a GD1 patient (N370S/L444P genotype) displayed an altered secretome 
that may contribute to the skeletal and immune problems in GD. Afterwards, 
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Mistry et al. (2010) provided an important model, using a conditional GBA1 
knockout in hematopoietic and mesenchymal cell lineages. They reported that 
the model recapitulated the main features of GD1, such as visceral and 
hematologic diseases together with a profound osteopenia. In addition, they 
provided evidences that whereas the mouse model had a normal osteoclast 
formation (osteoclastogenesis), the bone formation (osteoblastogenesis) 
appeared to be defective. They suggested that the osteoblastogenesis was 
inhibited by the accumulation of the lipids GlcCer and GlcSph, and their 
consequent interaction with the protein kinase C (PKC). Later on, the same 
authors proposed that the extralysosomal glucocerebrosidase GBA2 
transformed the increased levels in serum of GlcCer and, mainly, GlcSph in 
sphingosine, which inhibited osteoblasts survival (Mistry et al. 2014). Despite of 
these previous evidences, other studies confirmed a correlation between bone 
features and osteoclast number in GD (Bondar et al. 2017; Mucci et al. 2012, 
2013; Reed et al. 2013, 2018).  
 Several groups decided to use human induced Pluripotent Stem Cells 
(iPSC)-derived osteoblasts to address the unknown of the bone pathology in 
GD. The main study so far is the one recently published by Ricardo Feldman’s 
group (Panicker et al. 2018). They showed that GD iPSC-derived osteoblasts 
had developmental and lysosomal defects that impaired bone matrix deposition. 
Moreover, they showed that the canonical Wnt pathway was affected. In 
concordance, many studies showed the importance of this pathway in bone 
This article is protected by copyright. All rights reserved.
metabolism, including ours (Estrada et al. 2012, Zheng et al. 2015, Martínez-Gil 
et al. 2018). 
The clinical bone manifestations in GD are included in the bone 
remodeling problems category, since bone problems appear as a post-natal 
trait. Whether the osteoblasts are downregulated or the osteoclasts are 
upregulated is one of the main questions that needs to be answered in order to 
look for an effective treatment. 
 Our aim was to create osteoblasts derived from wild-type hiPSC 
generated in our group (Canals et al. 2015b) and compare them with those 
generated from GD patients [N370S/N370S, a gift from Ricardo Feldman, 
G202R/L444P, a gift from Gustavo Tiscornia (Tiscornia et al. 2011), and 
N370S/84GG (Park et al., 2008)]. For the MSC-like cells induction we used a 
multistep culture method, summarized in Fig. 2a. For each MSC induction (WT, 
N370S/N370S, G202R/L444P, N370S/84GG) the expression of specific MSC 
surface markers (CD73, CD90, CD105) and the absence of expression of 
hematopoietic markers (CD34 and CD45) were verified (data not shown). This 
qualitative step is required to continue with the subsequent experiments. From 
now on, the MSC-like cells will be mentioned as MSC. 
The MSCs with G202R/L444P and N370S/84GG genotypes presented 
lack of proliferation capacity and therefore could not be used in subsequent 
experiments. These cells were larger and flatter compared to the WT and 
N370S/N370S MSC (spindle-shaped cells in both cases). The lack of self-
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renewal of these large flattened cells has been previously described in the 
literature (Colter et al. 2000; Digirolamo et al. 1999). Because the relationship 
between cell size, morphology and senescence is well known (Bayreuther et al, 
1988; von Zglinicki et al, 2003), we evaluated the cell cycle profile in the MSC 
stage (in WT, N370S/N370S and N370S7/84GG genotypes) by flow cytometry 
as an attempt to investigate the possible alteration of the cell cycle in GD cells. 
As shown in Fig. 2b, there was a remarkable proportion (98%) of GD 
N370S/84GG cells arrested in G0/G1 phase compared to WT cells (88%). 
Concomitant with this, there was a reduction in the number of replicative cells 
(phase S, N370S/84GG MSC = 0.6% compared to WT MSC = 2.9%) and in the 
G2/M subpopulation (N370S/84GG MSC = 1.5% compared to WT = 8.7%). 
Regarding the other GD genotype (N370S/N370S), the number of cells in S 
phase had also notably decreased in comparison to WT cells (N370S/N370S 
MSC = 0.9%, WT MSC = 2.9%). The classic features characterizing the 
senescence phenotype of MSCs include growth arrest in the G1 phase of the 
cell cycle, enlarged or flattened morphology and increased expression of 
senesce-associated β-galactosidase (not evaluated because the β-
galactosidase activity in LSD is deregulated and could drive to 
misinterpretation). Thus, only GD cells with the N370S/N370S genotype were 
used in further experiments. 
To check the GBA1 activity before and after the differentiation process 
we analyzed the enzyme activity in the MSC stage (considered as day 0) and 
This article is protected by copyright. All rights reserved.
after 21 days of the osteogenic differentiation. We showed that both, on day 0 
and day 21, the activity of GBA1 in GD cells was less than 15% (GD day 0 = 
13%, GD day 21 =14%) compared to that of the WT cells. Moreover, the 
difference between GBA1 activity in WT and GD cells did not change during the 
differentiation process (Fig 2c).  
We aimed to evaluate in vitro the potential impact of GBA1 deficiency on 
two representative genes of the osteogenic development and mineralization 
process, runt-related transcription factor 2 (RUNX2) and tissue-nonspecific 
alkaline phosphatase (ALPL), by real time polymerase chain reaction (RT-
PCR). The expression of ALPL during the differentiation was significantly higher 
in GD compared to WT cells (Fig. 3a) Although this is in disagreement with 
other authors who found the expression of this gene lower in GD compared to 
WT (Mistry et al. 2010, Panicker et al. 2018), other studies have reported no 
significant differences in the mRNA levels of this gene between MSCs of GD 
and WT (Compeau et al, 2009). In the same direction, Lecourt et al. (2012) 
showed that the activity of this enzyme did not change in CBE-treated MSCs, 
indicating that the inhibition of the GBA1 enzyme does not impact in the 
expression of ALPL. Regarding RUNX2 expression along differentiation, higher 
levels were observed at day 7 in both genotypes (GD and WT), corresponding 
to the MSC to osteoblasts transition. At all time-points, the expression of 
RUNX2 was higher in WT cells (Fig. 3b). 
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To evaluate the osteoblast functionality and therefore the mineralization 
of the extracellular matrix, we confirmed the existence of hydroxyapatite crystals 
(the bone mineral content) by the staining of calcium (Fig. 4a) and phosphate 
(Fig. 4b).  Both, calcium and phosphate were observed from day 14 in WT and 
GD cells.  
The results of these experiments indicate that GD MSC seem to have a 
normal behavior, and they may differentiate properly to functional osteoblasts, 
in agreement with the model generated by Lecourt et al. (2012). We can 
assume that the GD cells have a normal bone development, as expected, since 
bone problems in GD are due to defects in bone remodeling and not in bone 
development. The differences between WT and GD in the expression of RUNX2 
and ALPL seem not to affect the function of GD osteoblasts. 
Since osteoblast function was unaffected, GD bone pathology could be 
due to an increase in osteoclasts formation (osteoclastogenesis) or function. 
Osteoclats are multinucleated, tartrate resistant acid phosphatase (TRAP) 
positive and bone resorbing giant cells derived from the differentiation and 
fusion of mononuclear hematopoietic progenitors’ cells in the 
monocyte/macrophage lineage. The osteoblast-lineage cells (MSC, pre-
osteoblasts, osteoblasts and osteocytes) play an essential role in the regulation 
of osteoclastogenesis.  
Osteoblast lineage cells and osteoclasts have a permanent crosstalk 
through molecules such as the receptor activator of the nuclear factor kappa B 
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(RANK) and its ligand (RANKL). Osteoblasts lineage cells express in their 
surface and release RANKL, that binds to the receptor RANK in the pre-
osteoclasts’ surface and promote osteoclasts’ differentiation, activation and 
survival. We performed co-cultures of MSC or osteoblasts derived either from 
wild-type or GD iPSC with monocytes from healthy donors (Fig.5a). The 
objective was to assess whether the osteoclastogenesis, promoted by the WT 
or GD iPSC-derived MSC/osteoblasts, was similar. With 4’,6-diamidino-2-
phenylindole (DAPI) and TRITC-phalloidin, we were able to compare the nuclei 
number and the size of the osteoclasts generated by the two osteoblastic 
lineages (Fig. 5b). The cells need to have at least three nuclei to be considered 
mature osteoclasts. The TRAP staining of these cells revealed the osteoclast 
identity (Fig. 5c). The osteoclasts generated by GD iPSC-derived 
MSC/osteoblasts were larger than the ones generated by WT MSC/osteoblasts 
(Fig. 5d). However, there were no differences in the number of nuclei per 
osteoclasts (Fig. 5e), indicating that the larger osteoclasts are probably due to 
an increased spreading, rather than to an increment of cell fusion. We also 
analyze TRAP released into the culture media because it has been reported 
that it is in good correlation with the number of mature osteoclasts generated 
(Alatalo et al, 2000). However, we did not find consistent differences between 
the values in both conditions, assuming that the number of osteoclasts 
generated either by WT or GD iPSC-derived MSC/osteoblasts was similar (data 
not shown). 
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In summary, the results presented here show that we were able to 
generate models of MSC and osteoblasts from GD- (and WT)-iPSC. However, it 
seems that these models do not reproduce faithfully the bone pathology in GD. 
Maybe the complexity of the bone pathology in this disease cannot be 
explained with cell-autonomous models. Similar to what had happened with 
previous cellular models, our model did not allow the evaluation of the direct 
cross-talking with other cells and other molecules such as the cytokines, which 
are known to be very important in the bone remodeling.  
 
Atypical femoral fracture 
The last example is that of a particular type of bone fracture, known as atypical 
femoral fracture (AFF). AFFs were defined as atraumatic or low‐trauma 
fractures located in the subtrochanteric region or femoral shaft. The diagnosis of 
AFF specifically excludes high trauma fractures, fractures of the femoral neck, 
intertrochanteric fractures with spiral subtrochanteric extension, pathological 
fractures associated with primary or metastatic bone tumors, and periprosthetic 
fractures. The fractures are usually not comminuted. Other characteristic 
radiographic features of AFFs (Fig. 6a) include a transverse fracture line at the 
point of origination in the lateral cortex. As the fracture propagates across the 
diaphysis to the medial cortex, the orientation may become more oblique and 
when it becomes complete, a prominent medial “spike” may be present. There 
may be a focal or diffuse periosteal reaction of the lateral cortex surrounding the 
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region where the fracture initiated. This reaction may appear as cortical 
“beaking” or “flaring” adjacent to a discrete transverse lucent fracture line or as 
focal thickening of the lateral cortex. Focal and diffuse endosteal reactions near 
the fracture site have been reported more recently. This focal cortical thickening 
represents cortical hypertrophy and may be unilateral or bilateral. There may 
also be generalized cortical thickening (Shane et al. 2014). Some 
epidemiological studies have suggested a relationship between AFFs and long-
term bisphosphonates (BPs) therapy, the main treatment for osteoporosis 
(Gedmintas et al. 2013; Liu et al. 2015). Denosumab treatment has also been 
related to AFFs (reviewed in Anastasilakis et al 2018), although this relationship 
is not so clear. In any case, the pathogenesis of AFFs has not yet been 
elucidated. 
 We studied three sisters who had atypical femoral fractures after 
receiving various oral bisphosphonates for 6 years (Roca-Ayats et al. 2017). 
Two of the sisters had a single fracture and one had bilateral fractures. Given 
the low incidence of atypical femoral fractures in the general population (3.0-9.8 
cases per 100,000 person-year, Khow et al. 2017), we hypothesized that these 
sisters might have an underlying genetic background that contributed to these 
fractures. 
We performed whole-exome sequencing in the three sisters and in three 
unrelated patients with atypical femoral fractures who each had received 
bisphosphonates for more than 5 years. We prioritized rare nonsynonymous 
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mutations in the variant filtering, and only mutations that were shared among 
the three sisters were considered. No mutation was found to be homozygous or 
in compound heterozygosity. 
Assuming that a dominant model was involved, we detected 37 rare 
mutations (in 34 genes), among them a novel p.Asp188Tyr substitution in the 
enzyme geranylgeranyl pyrophosphate synthase (GGPPS). This variant had the 
best conservation score and was not described in any of the available 
population databases. Interestingly, GGPPS is a homohexameric enzyme 
(Kavanagh et al. 2006a) that participates in the mevalonate (or isoprenoid) 
pathway (Fig. 6b), catalyzing a reaction just downstream of the main site of 
inhibition by bisphosphonates (Kavanagh et al. 2006b). The mevalonate 
pathway leads to the production of cholesterol and isoprenoid lipids, such as 
farnesyl diphosphate (FPP) and geranylgeranyl diphosphate (GGPP), required 
for the post-translational prenylation of some proteins, including small GTPases. 
Prenylation of small GTPases is necessary for their activation and essential for 
osteoclast function and survival (Itzstein et al. 2011). 
We performed in vitro functional analyses of the GGPPS p.Asp188Tyr 
mutation, which showed a severe reduction in enzyme activity together with 
mild oligomerization defects (Roca-Ayats et al. 2018b). Interestingly, another 
work on GGPPS p.Asp188Tyr mutation has been recently published 
(Lisnyansky et al. 2018) and the authors also observed a decreased catalytic 
activity of the mutated GGPPS, consistent with our results. In addition, they 
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showed that it is unable to support cross-species complementation. On the 
contrary, they only observed hexameric conformation of the enzyme in 
crystallographic experiments, although they saw a slight break of the tertiary 
symmetry, as well as a lower thermal stability of the mutated enzyme. In 
addition, the new tyrosine residue sterically interferes with substrate binding. 
Moreover, and considering that GGPPS can also be inhibited by BPs, although 
to a lesser extent (Guo et al. 2007), they studied the affinity of the GGPPS-
D188Y for zolendronate, a commonly used BP, demonstrating that it exhibited a 
reduction in the binding affinity although it could still be inhibited by 
zolendronate.  
We also performed cellular functional assays, such as RNAi knockdown 
of the GGPS1 gene in osteoblasts and in osteoclasts. In osteoblasts, RNAi 
produced a strong mineralization reduction and a reduced expression of the 
typical osteoblastic markers osteocalcin, osterix, and RANKL, whereas in 
osteoclasts, it led to an increase of osteoclast number with a lower resorption 
activity (Roca-Ayats et al. 2018b). 
We and others have shown that GGPPS p.Asp188Tyr mutation has an 
impact on protein function and relevant effects on bone cells, making it a strong 
candidate for AFF susceptibility. We propose that excessive inhibition of 
osteoclastic activity by the mutation plus BPs may lead to reduced bone 
remodeling and toughness, which may increase AFF susceptibility. 
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Few studies aiming to elucidate the genetics underlying AFF have been 
carried out, identifying some genes involved in AFF (Table 1). One of the most 
interesting genes is CYP1A1, an enzyme involved in the metabolism of drugs 
and xenobiotics and responsible for the hydroxylation of steroid hormones, such 
as estrogens (Zhou et al. 2009; Fig. 6b). Mutations in CYP1A1 were found in 
the 3 sisters and one unrelated patient in our study (Roca-Ayats et al. 2017, 
2018b) and also reported elsewhere in two patients with AFF and 
glucocorticoid-induced osteoporosis (Peris et al. 2018). Another study identified 
a missense variant in the PPEF2 gene significantly associated with AFF by 
exon array analysis of a small cohort (Pérez-Núñez et al. 2015). To date, this 
gene has no known function in bone metabolism. Some studies have identified 
genes previously known to be involved in monogenetic bone diseases. 
Recently, Funck-Brentano and colleagues (2017) identified a heterozygous 
mutation in COL1A2, coding for type 1 collagen, a major component of the bone 
extracellular matrix. Mutations in COL1A2 cause osteogenesis imperfecta (OI). 
However, no specific physical features of OI were identified in this patient, apart 
from short stature. In addition, Lau et al. (2017) identified a homozygous 
mutation in CTSK gene in a consanguineous family, encoding for cathepsin K 
and related to pycnodysostosis, although the patient identified had no clinical 
features of this disease. Finally, some cohort studies identified AFFs in patients 
of hypophosphatasia initially misdiagnosed with postmenopausal osteoporosis 
and treated with BPs (Peris et al. 2018, Sum et al. 2013). Heterozygous 
This article is protected by copyright. All rights reserved.
mutations in tissue non-specific alkaline phosphatase (TNSALP; ALPL gene) 
were identified. In these cases, it might be that mild, unrecognized forms of 
some monogenetic bone diseases underlie the etiology of AFFs. Taken 
together, all the genetic studies carried out in AFF patients advocate a 
heterogeneous genetic component of predisposition to AFF, in which each 
individual patient would be a carrier of different specific genetic variant/s (Fig. 
6c). In addition, in our study we identified some other interesting rare variants in 
the 3 sisters and unrelated patients (e.g. MMP9, MVD, RUNX2, NGEF, SYDE2, 
FN1; Roca-Ayats et al. 2018a), suggesting a polygenic or complex background 
involving, to different extent, several additional variants in the susceptibility to 
AFF. All in all, we speculate that an accumulation of a few susceptibility variants 
from different pathways and their interactions constitute the genetic 
predisposition that, together with BPs and/or other comorbid conditions, give 
rise to AFF, in what we might call “the perfect storm”. Further identification 
and/or replication of genetic variants, as well as functional studies of the 
identified variants, are needed to detect at-risk individuals for clinical decision-
making. 
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Figure Legends 
Fig. 1. Analysis of a pedigree with a mutation in the EXT2 gene. a) segregation 
analysis of EXT2 polymorphic markers. A-F refer to positions in the map shown 
in b. b) position of the polymorphic markers (A-F) genotyped in a, in relation to 
EXT2 exons. c) MLPA analysis of the DNA of the proband, her parents and her 
affected aunt, showing the heterozygous deletion of EXT2 exons 10-16 in the 
affected individuals. 
 
 
Fig. 2. a) Schematic diagram of the induction of Mesenchymal Stromal Cells 
(MSC) including 4 main steps: Embryonic Body (EB) formation, cell outgrowth 
from EBs on Matrigel-coated dishes, cell dissociation (3X) and monolayer 
culture b) Percentage of MSC in each phase of the cell cycle for the indicated 
genotypes. c) GBA1 activity in cells of both N370S/N370S and WT genotypes, 
at the indicated time points of the osteoblastic differentiation process. Results 
are shown as mean of GBA1 activity ± Standard Deviation (SD). GBA1 activity 
is expressed in nanomoles 4-Methylumbelliferone (MU) x mg-1 protein x hour-1. 
Statistical differences (***) p-value < 0.001, using Student’s t-test. See 
Supplementary Material and Methods for further details. 
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 Fig. 3. Relative mRNA expression of a) ALPL and b) RUNX2 genes during the 
osteoblastic induction (time points: 0 (MSC), 7, 14 and 21 days) in WT and GD 
(N370S/N370S) cells. Hypoxanthine phosphoribosyltransferase (HPRT) was 
used as a housekeeping gene. Data represent the mean values (9 replicates) 
normalized by WT day 0 (=WT MSC) ± SD. Statistical differences (**) p-value < 
0.01, (***) p-value < 0.001 and not significant (n.s) using Student’s t-test. See 
Supplementary Material and Methods for further details. 
 
 
Fig 4. Histochemical assays at 0, 7, 14 and 21 days of the osteoblastic 
differentiation process in both, WT and GD cells. a) alizarin red staining for 
calcium deposits, b) von Kossa staining for phosphate deposits. See 
Supplementary Material and Methods for further details. 
 
 
Fig. 5. a) Schematic representation of the co-culture experiment where the 
osteoclastogenesis of healthy monocytes induced by WT or GD iPSC-derived 
MSC/osteoblasts can be evaluated. A membrane separates the well in two 
compartments. The upper one contains the WT or GD iPSC-derived 
Mesenchymal Stromal Cells (MSC) or Osteoblasts (OB) and the bottom one 
contains the peripheral blood CD14+ monocytes from the same healthy female 
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donor. Molecules, such as RANKL, but not cells can cross the membrane.  b) 
TRITC-Phalloidin staining (in grey) for the actin cytoskeleton and 4’,6-diamidino-
2-phenylindole (DAPI) staining (in green) for the nuclei. c)  Tartrate resistant 
acid phosphatase (TRAP) staining (in purple/pink) as a specific marker for 
osteoclasts. d) Size and e) number of nuclei per osteoclast analyzed. The 
letters in the x axis:  a, b, c, d, e and f correspond to different healthy female 
donors, whose monocytes were distributed in two identical parts, one to assess 
osteoclastogenesis generated by the WT cells and the other for the generated 
by the GD cells. Results are showed as median ± confidence interval. Statistical 
differences (*) p-value < 0.05, (**) p-value < 0.01, (***) p-value <;0.001 and n.s, 
using Mann-Whitney-Wilcoxon test. See Supplementary Material and Methods 
for further details. 
 
 
Fig 6. a) Radiograph of an atypical femoral fracture. Note the transverse 
fracture line that becomes oblique as it progresses (white arrow). LC: focal 
thickening of the lateral cortex; MS: medial spike. b) Proteins found mutated in 
AFF patients (in bold) in the context of bone tissue. c)  Mevalonate pathway, 
indicating the steps affected by bisphosphonates (BPs, in red) and the position 
of GGPPS (circled in green).  
 
 
This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
JIMD_12097_Fig.2.jpg
This article is protected by copyright. All rights reserved.
JIMD_12097_Fig.3.jpg
This article is protected by copyright. All rights reserved.
JIMD_12097_Fig.4.jpg
This article is protected by copyright. All rights reserved.
JIMD_12097_Fig.5.jpg
This article is protected by copyright. All rights reserved.
JIMD_12097_Fig.6.jpg
This article is protected by copyright. All rights reserved.
This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/jimd.12097  
MATERIALS AND METHODS 
Culture of the induced Pluripotent Stem Cells (iPSC)  
The generation of the human Gaucher disease (GD) induced Pluripotent Stem 
Cells (iPSC) lines with the N370S/N370S (Panicker et al. 2012), G202R/L444P 
(Tiscornia et al. 2011) and N370S/84GG (Park et al. 2008) genotypes were 
previously described. Wild-type (WT) iPSC cells were generated by our group 
(Canals et al. 2015). They were maintained in human embryonic stem cells 
(HES) medium, consisting of knockout Dulbecco´s modified Eagle medium (KO-
DMEM; Gibco, Cat. No. 10829018) supplemented with 20% KO-serum 
replacement (Gibco, #10828010), 2mM Glutamax (Gibco, #35050061), 50mM 
2-mercaptoethanol (Gibco, Cat. No. 21985023), 1% Minimum Essential Media 
(MEM) non-essential amino acids (Gibco, Cat. No. 11140035), 1% 
penicillin/streptomycin (Gibco, Cat. No. 15140122) and 10ng/ml basic fibroblast 
growth factor (bFGF, Peprotech, Cat. No. 100-18B). Cultures were maintained 
on top of a human foreskin fibroblast feeder layer at 37°C and 5% CO2. The 
culture medium was changed every day.  
 
Induction of mesenchymal stem cell (MSC)-like cells 
Once feeder-iPSC colonies, maintained on MatrigelTM (BD Biosciences, Cat. 
No. 354277) and fed with HESc (HES conditioned with mouse embryonic 
fibroblast and supplemented with 4ng/ml bFGF) medium, were at approximately 
80% confluence in 100mm dishes, the protocol of embryonic body (EB) 
formation was started. Culture medium was aspirated and colonies were 
washed twice with phosphate buffered saline (PBS). Then, 0.05% Trypsin-
EDTA (Gibco, Cat. No. 25300104) was added to dissociate the colonies in small 
clusters. The resulting suspension was transferred to 50ml falcon tubes and the 
desired amount of HESc medium was added. A volume of 100-120μl of 
resuspended cells was loaded into each well of 96-V bottom-well microtiter 
plates and centrifuged at 800g for 10 min to form iPSC aggregates in HESc, 
that were placed at 37°C, 5% CO2 during 2-3 days. After this growing period, 
the EBs were obtained and they were kept in suspension for 2-3 more days. 
The formed EBs were transferred into 6-well plates coated with Matrigel and 
This article is protected by copyright. All rights reserved.
cultured in EB medium (consisting of KO-DMEM supplemented with 10% KO-
serum Replacement, 2mM Glutamax, 50mM 2-beta-marcaptoethanol, 1% MEM 
non-essential aminoacids and 1% penicillin/streptomycin) to let their outgrowth 
reach the confluence (it takes around 10-16 days). Then, the EB outgrowths 
were dissociated using 0.25% Trypsin-EDTA (Gibco, Cat. No. 25200056). The 
cells were subsequently resuspended in EB medium and seeded at a ratio of 
1:2. Subsequently, confluent cells were dissociated two more times with 0.25% 
Trypsin-EDTA to completely remove the pluripotent cells in our culture and to 
obtain homogenous monolayer of mesenchymal-like cells (this passage was 
considered as passage 0 of MSC-like cells and the cells were ready to their 
subsequent validation by flow cytometry). In this moment, most of the cells in 
culture had a fibroblast-like appearance. 
 
Flow cytometric analysis of cell surface antigens 
Expression of the cell surface antigen profile of MSCs was characterized using 
flow cytometry. MSC-like cells were harvested using 0.05% Trypsin/EDTA. After 
neutralization, single-cell suspension was washed in cold PBS. Then, around 
1x106 cells in 100µl PBS were incubated with each monoclonal antibody 
following the manufacturer’s instructions. The following conjugated mouse anti-
human antibodies were used in the analyses: brilliant violet TM 421-conjugated 
against CD34, allophycocyanin (APC)-cyanineTM 7-conjugated against CD45 as 
a non-specific MSC markers and APC-conjugated against CD73, fluorescein 
isothiocyanate-conjugated against CD90, phycoerythrin-conjugated against 
CD105 as specific MSC markers (all from BD Pharmingen, Cat. No. 562577, 
557833, 560847, 555595, 560839, respectively). After 30 min incubation on ice, 
cells were washed twice with cold PBS, followed by centrifugation at 400g for 5 
min. The pellet was resuspended with 300-500µl PBS. Unstained cells were 
used as a control. Samples were run on a Becton Dickinson Facscanflow 
cytometric system (BD Biosciences), and analysis was completed using a 
FlowJo Software (Tree Star Inc.). 
 
Culture of MSC-like cells 
MSC-like cells were maintained in 0.1% (W/V) gelatin-coated T75 flask with 
MSC medium, consisting of alpha-MEM (Gibco, Cat. No. 22561021), 
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supplemented with 10% fetal bovine serum (FBS; Hyclone Laboratories Inc., 
Cat No. SH3007103), 2mM Glutamax and 1% penicillin/streptomycin. Culture 
medium was changed every 3 days, and when the cells reached 80-90% 
confluence, they were subcultured using 0.05% Trypsin-EDTA. 
 
Cell cycle analysis 
Cell cycle analysis was assessed on MSC at passages 3-4. Cells were 
trypsinized and fixed with 70% ethanol for 2 hours. After ethanol removal, cells 
were washed twice with PBS and the pellet was incubated in a PBS solution 
containing 0.1% Triton-X-100, 10µg/ml propidium iodide (Sigma, Cat. No. 
P4170), and 2mg/ml Ribonuclease A (Sigma, Cat. No. R6513). Cell cycle 
analysis was performed by flow cytometry, and the proportion of cells in the 
G0/G1, S, and G2/M phase was calculated using the Cell Quest Pro software 
(BD Biosciences). 
 
Induction of osteogenic differentiation  
For osteogenic differentiation, cells were seeded in 6-well, 12-well, and 24-well 
culture dishes or 100mm dishes depending on the specific experiment. When 
cells achieved 80% confluence, osteogenic differentiation was induced with 
alpha-MEM (Gibco) supplemented with 10% FBS, 50µg/ml ascorbic acid 
(Sigma, Cat. No. BP461), 10mM β-glycerophosphate (Sigma, Cat. No. G9422), 
100nM dexamethasone (Sigma, Cat. No. D4902), and 1% 
penicillin/streptomycin. Medium was changed every 3 days during 21 days.  
 
Histochemical assays 
For histochemical staining, cultures were washed twice with PBS and fixed with 
4% (W/V) paraformaldehyde (PFA) for 10 min at room temperature and rinsed 
with double-distillated water.  
For calcium deposits, the fixed cultures were covered with a 40mM Alizarin Red 
solution, pH=4.1 (adjusted with 10% NH4OH) for 20 min and then rinsed with 
double-distilled water. Calcium deposits stained red. 
Phosphate deposits were assessed by the von Kossa technique. The fixed 
cultures were covered with a 1.0% (W/V) silver nitrate solution and kept for 1 
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hour under ultraviolet light. After rinsing twice with double-distilled water, a 5.0% 
(W/V) sodium thiosulphate was added for 2 min and then cultures were washed 
again. Phosphate deposits stained black. The cells were stored in Tris-buffered 
at light protected until photos were taken.  
 
Glucocerebrosidase (GBA1) activity measurement 
GBA1 enzyme activity measurement was performed at the MSC stage (day 0) 
and at 21st day of differentiation, using 4-methylumbelliferyl (4-MU) 
glucopyranoside as artificial substrate. Cells (seeded in 24-well culture dishes) 
were washed twice with PBS and 100µl of 5mM 4-MU in 0.1M acetate buffer 
(pH 5.2) was added to each well, up to a total volume of 160µl. Then the plates 
were incubated for 1 hour at 37°C and enzyme reaction was stopped with 2ml 
of 100mM glycine/NaOH, pH 10.7. The released fluorescence was measured at 
λex: 355nm; λem: 460nm. The experiment was performed 3 times with at least 6 
replicates per each point (stages 0 and 21 days). 
 
Real-time reverse transcription-polymerase chain reaction 
Total RNA was extracted from cells plated in 100mm dishes using the High 
Pure RNA Isolation Kit (Roche Applied Science, Cat. No. 11828665001). cDNA 
was prepared using the High Capacity cDNA Reverse Transcription kit (Applied 
Biosystems, Cat. No. 4368814) following the manufacturer’s instructions. Real-
time PCR was performed on a LightCycler 480 II system using the Universal 
Probe Library (Roche Applied Science, Cat. No. 05015243001) according to the 
manufacturer’s instructions. The specific primers, listed in table S1, for 
hypoxanthine phosphoribosyltransferase (HPRT), tissue-nonspecific alkaline 
phosphatase (ALPL) and runt-related transcription factor 2 (RUNX2) were 
designed using the Universal ProbeLibrary Assay Design Center software 
(Roche Applied Science, www.roche-applied-science.com). All the reactions 
were run in triplicate and 3 independent experiments with 3 replicates each 
were performed. The expression of HPRT was used as housekeeping gene to 
normalize the expression of ALPL and RUNX2.  
 
This article is protected by copyright. All rights reserved.
Table S1. List of primer sequences and Universal Probe number (Roche Applied Science) 
used for RT-PCR analysis 
Gene Forward (Fw) and Reverse (Rv) primer  
(5’ to 3’) 
Amplicon 
size  
Universal probe 
number  
ALPL Fw - GACGGACCCGTCACTCTC 
Rv- GTGCCCGTGGTCAATTCT 
109 bp #77 (Cat. No. 
04689003001) 
RUNX2 Fw- GGCGCATTTCAGATGATGA 
Rv- GCCCAGTTCTGAAGCACCT 
95 bp #87 (Cat. No. 
04689127001) 
HPRT Fw- GACCAGTCAACAGGGGACAT 
Rv- GTGTCAATTATATCTTCCACAATCAAG 
95 bp #22 (Cat. No. 
04686969001) 
 
Osteoclasts formation assay 
Human peripheral blood mononuclear cells (PBMC) were isolated from healthy 
female donors in accordance with the approved ethical procedures of Clinical 
Research Ethics Committee of Parc de Salut MAR. Monocytes, the osteoclast 
precursors, were isolated from peripheral blood mononuclear cells (PBMC) 
using Human Monocyte Enrichment Cocktail RosetteSepTM (Stemcell  
Technologies, Cat. No. 15028) following the manufacturer’s  instructions. After 
isolating the monocyte fraction, the CD14 marker, strongly expressed on 
monocytes, was determined by flow cytometry using a fluorochrome conjugated 
anti-CD14 antibody, usually obtaining a culture purity of 90% CD14+ cells. 
Peripheral blood CD14+ monocytes were seeded at 5 x 105 cells on 10mm glass 
cover slips (Marienfeld, Cat. No. 0111500) in 24-well plates. These cells were 
incubated for 2 hours at 37°C in 5% CO2 in complete medium, consisting in the 
following: alpha-MEM, supplemented with 10% FBS, 2mM Glutamax, 1% 
penicillin/streptomycin and 25ng/ml of recombinant human macrophage colony 
stimulating factor M-CSF(R&D systems, Cat. No. 216-MC). Non-adherent cells 
were washed out and adherent cells were used for the osteoclast formation 
assays. The M-CSF in the media was kept during 3 days to induce monocytes 
to differentiate into preosteoclasts. On the third day, WT or GD iPSC-derived 
Mesenchymal Stromal Cells (MSC) or Osteoblasts (OB) were seeded at 6.5 mm 
Transwell with 0.4 μm pore polycarbonate membranes (Corning, Cat. No. 3413) 
that were inserted in the 24-well plate containing the preosteoclasts. All the 
cultures were maintained until the generation of multinucleated giant cells, 
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which occurred at around 24-28 days of culture. Culture medium was changed 
every 3 days.  
 
 
Phalloidin and DAPI staining 
Osteoclasts have a ring structure composed of actin. This actin ring is a 
hallmark of the degradative capacity of functional osteoclasts, without this actin 
ring, osteoclasts cannot resorb bone efficiently. The obtained osteoclasts were 
washed with PBS and fixed with 3.7% (W/V) PFA for 10 min. Cells were 
permeabilized with 0.1% Triton-X-100 in PBS for 3-5 min. The cytoskeletal actin 
was stained with TRITC-Phalloidin (Sigma, Cat. No. P1951) and cell nuclei with 
4’,6-Diamidino-2-phenylindole dihydrochloride (DAPI; Sigma, D9542). Images 
were acquired with an SP2 confocal system (Leica). In each multinucleated cell 
(more than 3 nuclei) the number of nuclei was counted and the area was 
measured using the using Fiji/ImageJ sofware. 
 
 
Tartrate-resistant acid phosphatase (TRAP) histochemical staining 
The obtained osteoclasts were washed with PBS and the TRAP staining was 
performed using a leukocyte acid phosphatase kit (Sigma, Cat. No. 387) 
following the manufacture’s recommended protocol. TRAP-positive osteoclasts 
were visualized under a phase-contrast microscope. 
 
Statistical analysis 
Statistical differences (*) p-value < 0.05, (**) p-value < 0.01, (***) p-value 
<;0.001 and not significant (n.s), were assessed using two-tailed unpaired 
Student’s t-test or Mann-Whitney-Wilcoxon test, as appropriate.  
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